Allergy Therapeutics
AGY · AIM · Health Care · mcap £306m today
All announcements
-
29 Jul 26Trading update for the year ended 30 June 2026
("Allergy Therapeutics" or the "Company" or the "Group")
RNS 9692293 ↗ -
28 Jul 26Appointment of Executive Chairman
28 July 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces the appointment of Helge Weiner-Trapness as Executive Chairman.
RNS 9689946 ↗ -
30 Jun 26Vesting of Options under Long-Term Incentive PlanRNS 9643017 ↗
-
15 Jun 26Long Term Incentive Awards
15 June 2026 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, announces that on 13 June 2026 it made a new long term incentive award (the "LTIP Award") to Shaun Furlong, its...
RNS 9617239 ↗ -
12 Jun 26Allergy Therapeutics to present at EAACI 2026
Allergy Therapeutics to present pollen and food allergy research data
RNS 9614850 ↗ -
31 Mar 26
-
12 Mar 26PDMR Dealings & Shareholding UpdateRNS 9470353 ↗
-
04 Mar 26Positive Biomarker Results from PROTECT Trial
Positive biomarker results from the PROTECT Phase I/IIa trial following achievement of the primary safety endpoint
RNS 9457118 ↗ -
26 Feb 26Allergy Therapeutics presents progress at AAAAI
Allergy Therapeutics presents further scientific progress in its pollen and food-allergy research portfolio at the 2026 AAAAI Annual Meeting
RNS 9447716 ↗ -
23 Feb 26Update on funding and total voting rights
23 February 2026 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today provides an update on the Group's funding and working capital position.
RNS 9442083 ↗ -
30 Jan 26Chief Strategy Officer and Board appointments
Allergy Therapeutics announces the appointments of Helge Weiner-Trapness as Chief Strategy Officer and Executive Director, and Lawrence Allen Wang as Independent Non-Executive Director
RNS 9395705 ↗ -
29 Jan 26Result of AGMRNS 9394264 ↗
-
28 Jan 26Grant of Options under Long Term Incentive SchemeRNS 9392170 ↗
-
19 Jan 26
-
06 Jan 26Notice of AGM
06 January 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, has today published its Notice of Annual General Meeting following publication of the Annual Report and...
RNS 9334985 ↗ -
29 Dec 25Result of General Meeting
Results of General Meeting and Posting of Annual Report 2025
RNS 9322781 ↗ -
16 Dec 25Grassmuno® marketing authorisation in Germany
("Allergy Therapeutics" or the "Company" or the "Group")
RNS 9298692 ↗ -
12 Dec 25Authority for allotment of New Shares
Authority for allotment of up to 610,000,000 New Shares and disapplication of pre-emption rights to facilitate a Potential Equity Raise
RNS 9292047 ↗ -
11 Dec 25Prelim Results and publication of Annual Report
("Allergy Therapeutics" or the "Group" or the "Company")
RNS 9289243 ↗ -
09 Dec 25Primary Safety Endpoint Met in PROTECT trial
PROTECT Phase I/IIa trial meets primary safety endpoint at highest planned dose
RNS 9283783 ↗ -
06 Nov 25Company to Evaluate Dual Listing on HKEX
Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company")
RNS 9216383 ↗ -
30 Oct 25G308 Phase III Year 2 Patient Screening Starts
Grass MATA MPL in paediatric patients - commencement of patient screening
RNS 9202781 ↗ -
29 Oct 25Warrant Exercise and Paydown of Debt
Repayment of the Entire Balance under the Shareholder Facility
RNS 9200418 ↗ -
16 Oct 25Further progress in Phase I/IIa PROTECT trial
Allergy Therapeutics announces further positive progress in Phase I/IIa PROTECT trial evaluating safety and tolerability of short-course peanut allergy vaccine candidate
RNS 9174004 ↗
Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.